$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000110465913039699 Filed on May 09, 2013

Income Statement

Concept	2013 Q2	2013 Q1	2012 Q1
Revenue	$0.00	$0.00	$7.774M
YoY Change	-100.0%	-100.0%	30.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.830M	$4.820M	$4.100M
YoY Change	-17.01%	17.56%	-6.82%
% of Gross Profit
Research & Development	$10.73M	$11.99M	$14.00M
YoY Change	-21.85%	-14.39%	25.88%
% of Gross Profit
Depreciation & Amortization	$450.0K	$440.0K	$420.0K
YoY Change	2.27%	4.76%	-4.55%
% of Gross Profit
Operating Expenses	$16.01M	$17.25M	$18.52M
YoY Change	-19.91%	-6.85%	16.0%
Operating Profit	-$16.01M	-$17.25M	-$10.75M
YoY Change	71.23%	60.55%	7.46%
Interest Expense	$9.000K	$10.00K	$43.00K
YoY Change	-40.0%	-76.74%	-10.42%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change	-100.0%		-100.0%
Pretax Income	-$15.35M	-$17.46M	-$13.14M
YoY Change	64.28%	32.89%	-1.6%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$15.35M	-$17.46M	-$13.14M
YoY Change	64.28%	32.89%	-1.6%
Net Earnings / Revenue			-168.99%
Basic Earnings Per Share
Diluted Earnings Per Share	-$309.4K	-$351.9K	-$346.8K
COMMON SHARES
Basic Shares Outstanding	49.63M shares	49.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q2	2013 Q1	2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$74.20M	$84.80M	$108.2M
YoY Change	-22.55%	-21.63%	15.35%
Cash & Equivalents	$23.48M	$26.74M	$24.52M
Short-Term Investments	$50.70M	$58.00M	$83.70M
Other Short-Term Assets	$1.978M	$1.753M	$2.789M
YoY Change	-26.74%	-37.15%	21.26%
Inventory
Prepaid Expenses
Receivables	$1.000M	$1.300M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$77.18M	$87.81M	$115.3M
YoY Change	-26.98%	-23.83%	15.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.715M	$4.962M	$5.073M
YoY Change	-14.27%	-2.19%	130.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$442.0K	$442.0K	$442.0K
YoY Change	10.5%	0.0%	47.33%
Total Long-Term Assets	$5.157M	$5.404M	$5.515M
YoY Change	-12.59%	-2.01%	112.12%
TOTAL ASSETS
Total Short-Term Assets	$77.18M	$87.81M	$115.3M
Total Long-Term Assets	$5.157M	$5.404M	$5.515M
Total Assets	$82.34M	$93.22M	$120.8M
YoY Change	-26.22%	-22.84%	17.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.000M	$6.400M	$8.400M
YoY Change	-1.1%	-23.81%	13.51%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$400.0K	$400.0K	$1.100M
YoY Change	-50.0%	-63.64%	-15.38%
Total Short-Term Liabilities	$9.967M	$7.995M	$17.77M
YoY Change	-44.04%	-55.0%	7.02%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$200.0K	$600.0K
YoY Change	-80.0%	-66.67%	-14.29%
Other Long-Term Liabilities	$32.70M	$31.70M	$21.70M
YoY Change	62.69%	46.08%	-32.4%
Total Long-Term Liabilities	$32.80M	$31.90M	$22.30M
YoY Change	59.22%	43.05%	-32.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.967M	$7.995M	$17.77M
Total Long-Term Liabilities	$32.80M	$31.90M	$22.30M
Total Liabilities	$42.80M	$39.90M	$40.00M
YoY Change	11.46%	-0.25%	-19.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$351.7M	-$336.3M	-$283.2M
YoY Change		18.75%
Common Stock	$391.3M	$389.7M	$364.0M
YoY Change		7.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$39.56M	$53.34M	$80.78M
YoY Change
Total Liabilities & Shareholders Equity	$82.34M	$93.22M	$120.8M
YoY Change	-26.22%	-22.84%	17.74%

Cashflow Statement

Concept	2013 Q2	2013 Q1	2012 Q1
OPERATING ACTIVITIES
Net Income	-$15.35M	-$17.46M	-$13.14M
YoY Change	64.28%	32.89%	-1.6%
Depreciation, Depletion And Amortization	$450.0K	$440.0K	$420.0K
YoY Change	2.27%	4.76%	-4.55%
Cash From Operating Activities	-$10.26M	-$13.90M	-$8.040M
YoY Change	-7.82%	72.89%	-39.59%
INVESTING ACTIVITIES
Capital Expenditures	-$210.0K	$372.0K	$3.082M
YoY Change	-75.58%	-87.93%	4240.85%
Acquisitions
YoY Change
Other Investing Activities	$7.300M	$7.140M	-$53.61M
YoY Change	-56.39%	-113.32%	-554.71%
Cash From Investing Activities	$7.100M	$6.770M	-$56.69M
YoY Change	-55.29%	-111.94%	-583.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$62.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-100.0K	-100.0K	63.58M
YoY Change	-75.61%	-100.16%	-19968.75%
NET CHANGE
Cash From Operating Activities	-10.26M	-13.90M	-8.040M
Cash From Investing Activities	7.100M	6.770M	-56.69M
Cash From Financing Activities	-100.0K	-100.0K	63.58M
Net Change In Cash	-3.260M	-7.230M	-1.150M
YoY Change	-175.12%	528.7%	-39.79%
FREE CASH FLOW
Cash From Operating Activities	-$10.26M	-$13.90M	-$8.040M
Capital Expenditures	-$210.0K	$372.0K	$3.082M
Free Cash Flow	-$10.05M	-$14.27M	-$11.12M
YoY Change	-2.14%	28.32%	-16.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33971000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26736000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	65151000	USD
CY2013Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	58015000	USD
CY2012Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3225000	USD
CY2013Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	1308000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2270000	USD
CY2013Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1753000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	87812000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5029000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4962000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	442000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	442000	USD
CY2012Q4	us-gaap	Assets Assets	110088000	USD
CY2013Q1	us-gaap	Assets Assets	93216000	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8845000	USD
CY2013Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6427000	USD
CY2012Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	398000	USD
CY2013Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	398000	USD
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49631672	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Assets Current AssetsCurrent	104617000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9243000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7995000	USD
CY2013Q1	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	31685000	USD
CY2012Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	299000	USD
CY2013Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	199000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	556000	USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	556000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	387539000	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	389113000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-318889000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-336347000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	69220000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	53337000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110088000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93216000	USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8872000	USD
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49631672	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49631672	shares
CY2012Q1	fold	Research Revenue ResearchRevenue	6114000	USD
CY2012Q1	fold	Collaboration Revenue CollaborationRevenue	1660000	USD
CY2012Q1	us-gaap	Sales Revenue Net SalesRevenueNet	7774000	USD
CY2012Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	420000	USD
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	18519000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-10745000	USD
CY2012Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000	USD
CY2012Q1	us-gaap	Interest Expense InterestExpense	43000	USD
CY2012Q1	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	2376000	USD
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13137000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-13137000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13137000	USD
CY2012Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	30418000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8501000	USD
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49631672	shares
	us-gaap	Operating Expenses OperatingExpenses	480495000	USD
CY2012Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14004000	USD
CY2012Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4095000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37887520	shares
	us-gaap	Sales Revenue Net SalesRevenueNet	121875000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1522000	USD
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	1030000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	17251000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-358620000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17251000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	252000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17458000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-345055000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8708000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-336347000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-17458000	USD
	fold	Deemed Dividend DeemedDividend	19424000	USD
	fold	Preferred Stock Accretion PreferredStockAccretion	802000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-356573000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17458000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	33000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13104000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	1000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	15000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	15000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17457000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-336332000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	525000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1388000	USD
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	522000	USD
	fold	Share Based Compensation Non Employees ShareBasedCompensationNonEmployees	853000	USD
	fold	Stock Based License Payments StockBasedLicensePayments	1220000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	418000	USD
	fold	Beneficial Conversion Feature Related To Bridge Financing BeneficialConversionFeatureRelatedToBridgeFinancing	135000	USD
CY2012Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-742000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3114000	USD
CY2012Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-267000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1259000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8039000	USD
CY2012Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	14300000	USD
CY2012Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	67906000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3082000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-56688000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13900000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-242252000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-76701000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	6765000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62063000	USD
CY2012Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	313000	USD
CY2012Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	837000	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	995000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	63582000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1145000	USD
CY2012Q1	us-gaap	Interest Paid InterestPaid	20000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000	USD
CY2010Q1	fold	Portion Of Share Purchased In One Unit PortionOfSharePurchasedInOneUnit	0.375	shares
CY2010Q1	fold	Warrant Term WarrantTerm	P4Y
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5587000	USD
	fold	Conversion Of Warrants To Common Stock ConversionOfWarrantsToCommonStock	386000	USD
	fold	Conversion Of Notes Payable To Preferred Stock ConversionOfNotesPayableToPreferredStock	5000000	USD
	fold	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	148951000	USD
	fold	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	802000	USD
	fold	Beneficial Conversion Feature Related To Issuance Of Series C Redeemable Convertible Preferred Stock BeneficialConversionFeatureRelatedToIssuanceOfSeriesCRedeemableConvertiblePreferredStock	19424000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-100000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	345689000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-7235000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	26736000	USD
	fold	Proceeds From Exercise Of Warrants Common And Preferred ProceedsFromExerciseOfWarrantsCommonAndPreferred	264000	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	5611000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	143022000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25668000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24523000	USD
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS INC
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49631672	shares
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2010Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4950000	shares
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1900000	shares
CY2010Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17100000	USD
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	11500000	shares
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62000000	USD
CY2010Q1	fold	Exercise Period Of Warrant On Or After Issued ExercisePeriodOfWarrantOnOrAfterIssued	P6M
CY2010Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	4.43
CY2010Q1	fold	Proceeds From Issuance Of Common Stock Gross ProceedsFromIssuanceOfCommonStockGross	18500000	USD
CY2013Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1400000	shares
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	28000	USD
CY2012Q4	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	99122000	USD
CY2013Q1	fold	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	84751000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3300000	USD
CY2013Q1	fold	Fair Value Inputs Number Of Inputs Used In Fair Value Classification FairValueInputsNumberOfInputsUsedInFairValueClassification	6	item
CY2013Q1	fold	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	262000	USD
CY2012Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.726	pure
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	33971000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	26736000	USD
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	11000	USD
CY2013Q1	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	13000	USD
CY2012Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	99108000	USD
CY2013Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	84736000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	25000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	33100000	USD
CY2013Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	26100000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2013Q1	fold	Common Stock Voting Rights For Each Share Held CommonStockVotingRightsForEachShareHeld	1	item
CY2012	fold	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	500000	shares
CY2012Q1	us-gaap	Share Price SharePrice	5.70
CY2012Q1	fold	Proceeds From Issuance Of Common Stock Gross ProceedsFromIssuanceOfCommonStockGross	65600000	USD
CY2010Q1	fold	Stock Issued During Period Shares Collaboration Agreement StockIssuedDuringPeriodSharesCollaborationAgreement	4900000	shares
CY2010Q1	fold	Number Of Shares Of Common Stock Sold In One Unit NumberOfSharesOfCommonStockSoldInOneUnit	1	shares
CY2013Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.988	pure
CY2012Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0031	pure
CY2013Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0013	pure
CY2012Q1	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y11M1D
CY2010Q1	fold	Number Of Warrants Sold In One Unit NumberOfWarrantsSoldInOneUnit	1	shares
CY2013Q1	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P11M1D
CY2012Q1	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013Q1	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1574000	USD

Files In Submission

Name	View Source	Status
0001104659-13-039699-index-headers.html	Edgar Link	pending
0001104659-13-039699-index.html	Edgar Link	pending
0001104659-13-039699.txt	Edgar Link	pending
0001104659-13-039699-xbrl.zip	Edgar Link	pending
a13-8599_110q.htm	Edgar Link	pending
a13-8599_1ex31d1.htm	Edgar Link	pending
a13-8599_1ex31d2.htm	Edgar Link	pending
a13-8599_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
fold-20130331.xml	Edgar Link	completed
fold-20130331.xsd	Edgar Link	pending
fold-20130331_cal.xml	Edgar Link	unprocessable
fold-20130331_def.xml	Edgar Link	unprocessable
fold-20130331_lab.xml	Edgar Link	unprocessable
fold-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2013 Q2 Form 10-Q Financial Statement

#000110465913039699 Filed on May 09, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2013 Q2 Form 10-Q Financial Statement

#000110465913039699 Filed on May 09, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold